FDA Seeks Input on Improving Access to Nonprescription Medications
Published Date: 12/2/2025
Notice
Summary
The FDA wants your ideas on how to make it easier for people to get nonprescription drugs, like over-the-counter medicines. They’re gathering feedback now to help plan a public meeting in 2026. If you have thoughts, send them by February 2, 2026—this could lead to faster, cheaper access for everyone!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
NDA pathway requires consumer-use studies
If you seek to market a nonprescription drug via a new drug application (NDA) under section 505, you must submit adequate tests and substantial evidence that the drug is safe and effective for self-use. FDA often requires consumer studies—such as label comprehension, self-selection, actual use, and human factors studies—and typically requires more data when less is known about nonprescription use.
Public input open — comments due Feb 2, 2026
The FDA is asking the public—drug developers, health care providers, and consumers—to send ideas on how to increase access to nonprescription (over-the-counter) drugs. You can submit electronic or written comments that must be received by February 2, 2026; FDA will use the feedback to plan a public meeting in calendar year 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13778 — Medical Device User Fee Amendments; Public Meeting; Request for Comments
The FDA is planning a public meeting on August 5, 2026, to talk about renewing fees that medical device makers pay to help speed up device reviews from 2028 to 2032. This affects companies making medical devices and could impact how much they pay and how fast their products get approved. The current fee program ends in September 2027, so the FDA wants your thoughts before finalizing new rules and fees.
2026-13716 — New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA just updated the rules for new animal drugs, approving several new and generic medicines for pets and farm animals from early 2026. These changes help keep animal treatments safe and effective, and the updates take effect right away on July 7, 2026. If you’re a drug maker or animal caretaker, these approvals and sponsor changes could impact what medicines are available and when.
2026-13519 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Approval of Medical Devices
The FDA is asking for public feedback on their paperwork rules for approving the most important and risky medical devices, like life-support machines. This review helps keep devices safe and effective before they hit the market. If you have thoughts, you’ve got until August 5, 2026, to share them—no cost changes, just a check-in on the info they collect.
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
Previous / Next Documents
Previous: 2025-21727 — Combined Notice of Filings #1
The Federal Energy Regulatory Commission got several filings from energy companies like Public Service Company of New Mexico and Aron Energy Prepay LLCs about updates to electric rates and company status. These changes could affect how energy prices and rules work, with some updates set to take effect as soon as May or August 2025. If you want to comment, deadlines are coming up fast in November and December 2025.
Next: 2025-21729 — Records Governing Off-the-Record Communications; Public Notice
The Federal Energy Regulatory Commission (FERC) is sharing updates about off-the-record communications in ongoing cases. They remind everyone that some secret chats can’t affect decisions unless fairness calls for it, while others are part of the official record. This keeps the process fair and transparent, with no new costs or deadlines announced.